Antibody responses against SARS-CoV-2 in COVID-19 patients.
作者信息
Liu Anding, Li Ying, Peng Jing, Huang Yuancheng, Xu Dong
机构信息
Experimental Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Clinical Laboratory, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
出版信息
J Med Virol. 2021 Jan;93(1):144-148. doi: 10.1002/jmv.26241. Epub 2020 Aug 2.
Abstract
摘要
相似文献
1
Antibody responses against SARS-CoV-2 in COVID-19 patients.COVID-19患者针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的抗体反应。
J Med Virol. 2021 Jan;93(1):144-148. doi: 10.1002/jmv.26241. Epub 2020 Aug 2.
2
Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.COVID-19 患者症状出现后七个月内 SARS-CoV-2 特异性和中和抗体的动力学。
Microbiol Spectr. 2021 Oct 31;9(2):e0059021. doi: 10.1128/Spectrum.00590-21. Epub 2021 Sep 22.
3
Serological investigation of asymptomatic cases of SARS-CoV-2 infection reveals weak and declining antibody responses.无症状 SARS-CoV-2 感染病例的血清学调查显示，抗体反应较弱且逐渐减弱。
Emerg Microbes Infect. 2021 Dec;10(1):905-912. doi: 10.1080/22221751.2021.1919032.
4
Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection.新冠病毒感染后6个月内肾移植受者体内抗新冠病毒抗体的下降与丧失
Kidney Int. 2021 Feb;99(2):486-488. doi: 10.1016/j.kint.2020.12.001.
5
Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.基于 COVID-19 患者队列的 SARS-CoV-2 抗体的长期动力学和灭活疫苗对 SARS-CoV-2 抗体的影响。
Front Immunol. 2022 Jan 27;13:829665. doi: 10.3389/fimmu.2022.829665. eCollection 2022.
6
SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection.严重急性呼吸综合征冠状病毒 2 型抗体：IgA 与 COVID-19 感染早期疾病的严重程度相关。
J Med Virol. 2021 Sep;93(9):5409-5415. doi: 10.1002/jmv.27058. Epub 2021 May 12.
7
Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China.中国北京一家三级甲等医院中新冠病毒肺炎患者抗体反应的纵向分析
Front Immunol. 2021 Mar 15;12:614436. doi: 10.3389/fimmu.2021.614436. eCollection 2021.
8
Seroconversion and kinetic of anti SARS-COV-2 antibodies in 25 patients with hematological malignancies who recovered from SARS-COV-2 infection.25例从新型冠状病毒肺炎感染中康复的血液系统恶性肿瘤患者的血清转化及抗新型冠状病毒2抗体动力学
Hematol Oncol. 2021 Aug;39(3):428-431. doi: 10.1002/hon.2872. Epub 2021 May 5.
9
Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients.严重和中度 COVID-19 患者的抗体和细胞因子谱存在差异。
Front Immunol. 2021 Aug 19;12:723585. doi: 10.3389/fimmu.2021.723585. eCollection 2021.
10
Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).儿童多系统炎症综合征（MIS-C）中 SARS-CoV-2 血清学的定量分析。
Pediatrics. 2020 Dec;146(6). doi: 10.1542/peds.2020-018242. Epub 2020 Sep 2.
引用本文的文献
1
Pre-existing IgG antibodies to HCoVs NL63 and OC43 Spike increased during the pandemic and after COVID-19 vaccination.在大流行期间以及接种新冠疫苗后，针对人冠状病毒NL63和OC43刺突蛋白的预先存在的IgG抗体有所增加。
Heliyon. 2025 Jan 22;11(3):e42171. doi: 10.1016/j.heliyon.2025.e42171. eCollection 2025 Feb 15.
2
Humoral and T cell responses to SARS-CoV-2 reveal insights into immunity during the early pandemic period in Pakistan.体液免疫和 T 细胞应答对 SARS-CoV-2 的反应揭示了在巴基斯坦大流行早期期间的免疫情况。
BMC Infect Dis. 2023 Dec 1;23(1):846. doi: 10.1186/s12879-023-08829-1.
3
Antigenicity and immunogenicity of SARS-CoV-2 surface glycoprotein fragment in CHO cells.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）表面糖蛋白片段在CHO细胞中的抗原性和免疫原性
Iran J Microbiol. 2023 Feb;15(1):128-137. doi: 10.18502/ijm.v15i1.11929.
4
Diagnostic TR-FRET assays for detection of antibodies in patient samples.用于检测患者样本中抗体的诊断 TR-FRET 分析。
Cell Rep Methods. 2023 Feb 20;3(3):100421. doi: 10.1016/j.crmeth.2023.100421. eCollection 2023 Mar 27.
5
Optimisation and Validation of a conventional ELISA and cut-offs for detecting and quantifying anti-SARS-CoV-2 Spike, RBD, and Nucleoprotein IgG, IgM, and IgA antibodies in Uganda.优化和验证常规 ELISA 方法及其 cutoff 值，以用于在乌干达检测和定量抗 SARS-CoV-2 刺突蛋白、受体结合域以及核衣壳蛋白 IgG、IgM 和 IgA 抗体。
Front Immunol. 2023 Mar 14;14:1113194. doi: 10.3389/fimmu.2023.1113194. eCollection 2023.
6
Safety of mRNA COVID-19 vaccinations in patients with allergic diseases.新冠病毒mRNA疫苗在过敏性疾病患者中的安全性。
Public Health Pract (Oxf). 2023 Jun;5:100354. doi: 10.1016/j.puhip.2022.100354. Epub 2022 Dec 24.
7
Longevity and Mechanism of Heterosubtypic Protection Induced by M2SR (M2-Deficient Single-Replication) Live Influenza Virus Vaccine in Mice.M2SR（M2缺陷单复制）活流感病毒疫苗在小鼠中诱导的异亚型保护的寿命及机制
Vaccines (Basel). 2022 Dec 13;10(12):2131. doi: 10.3390/vaccines10122131.
8
Assessment of the post-SARS-CoV-2 vaccination response depending on the epidemiological status, demographic parameters and levels of selected cytokines in medical personnel.根据医务人员的流行病学状况、人口统计学参数和所选细胞因子水平评估新冠病毒疫苗接种后的反应
Postepy Dermatol Alergol. 2022 Oct;39(5):913-922. doi: 10.5114/ada.2022.120884. Epub 2022 Nov 9.
9
Novel coronavirus mutations: Vaccine development and challenges.新型冠状病毒突变：疫苗开发与挑战。
Microb Pathog. 2022 Dec;173(Pt A):105828. doi: 10.1016/j.micpath.2022.105828. Epub 2022 Oct 13.
10
Discovery and characterization of SARS-CoV-2 reactive and neutralizing antibodies from humanized CAMouse mice through rapid hybridoma screening and high-throughput single-cell V(D)J sequencing.通过快速杂交瘤筛选和高通量单细胞 V(D)J 测序，从人源化 CAMouse 小鼠中发现和鉴定 SARS-CoV-2 反应性和中和抗体。
Front Immunol. 2022 Sep 23;13:992787. doi: 10.3389/fimmu.2022.992787. eCollection 2022.
本文引用的文献
1
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.无症状 SARS-CoV-2 感染的临床和免疫学评估。
Nat Med. 2020 Aug;26(8):1200-1204. doi: 10.1038/s41591-020-0965-6. Epub 2020 Jun 18.
2
Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.新型冠状病毒感染恢复期个体中 SARS-CoV-2 特异性体液和细胞免疫的检测。
Immunity. 2020 Jun 16;52(6):971-977.e3. doi: 10.1016/j.immuni.2020.04.023. Epub 2020 May 3.
3
Antibody responses to SARS-CoV-2 in patients with COVID-19.新型冠状病毒肺炎（COVID-19）患者的 SARS-CoV-2 抗体反应。
Nat Med. 2020 Jun;26(6):845-848. doi: 10.1038/s41591-020-0897-1. Epub 2020 Apr 29.
4
Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period.预测 SARS-CoV-2 的传播动力学，直至大流行后期。
Science. 2020 May 22;368(6493):860-868. doi: 10.1126/science.abb5793. Epub 2020 Apr 14.
5
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019.新型冠状病毒病 2019 患者的 SARS-CoV-2 抗体反应。
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034. doi: 10.1093/cid/ciaa344.
6
Clinical and immunological features of severe and moderate coronavirus disease 2019.新型冠状病毒病 2019 重症和中度患者的临床和免疫学特征。
J Clin Invest. 2020 May 1;130(5):2620-2629. doi: 10.1172/JCI137244.
7
Antibodies in Infants Born to Mothers With COVID-19 Pneumonia.母亲患有 COVID-19 肺炎的婴儿体内的抗体。
JAMA. 2020 May 12;323(18):1848-1849. doi: 10.1001/jama.2020.4861.
8
SARS-CoV-2: virus dynamics and host response.严重急性呼吸综合征冠状病毒2：病毒动力学与宿主反应
Lancet Infect Dis. 2020 May;20(5):515-516. doi: 10.1016/S1473-3099(20)30235-8. Epub 2020 Mar 23.
9
Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus.中东呼吸综合征冠状病毒抗体的持续性
Emerg Infect Dis. 2016 Oct;22(10):1824-6. doi: 10.3201/eid2210.160706. Epub 2016 Oct 15.
10
Disappearance of antibodies to SARS-associated coronavirus after recovery.康复后与严重急性呼吸综合征相关冠状病毒抗体的消失。
N Engl J Med. 2007 Sep 13;357(11):1162-3. doi: 10.1056/NEJMc070348.
Zotero 插件